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ABSTRACT
Background. Sentinel lymph node (SLN) mapping in
colorectal cancer may have prognostic and therapeutic
signiﬁcance; however, currently available techniques are
not optimal. We hypothesized that the combination of
invisible near-infrared (NIR) ﬂuorescent light and ex vivo
injection could solve remaining problems of SLN mapping
in colorectal cancer.
Methods. The FLARE imaging system was used for real-
time identiﬁcation of SLNs after injection of the NIR
lymphatic tracer HSA800 in the colon and rectum of
(n = 4) pigs. A total of 32 SLN mappings were performed
in vivo and ex vivo after oncologic resection using an
identical injection technique. Guided by these results, SLN
mappings were performed in ex vivo tissue specimens of
24 consecutive colorectal cancer patients undergoing
resection.
Results. Lymph ﬂow could be followed in real-time from
the injection site to the SLN using NIR ﬂuorescence. In
pigs, the SLN was identiﬁed in 32 of 32 (100%) of SLN
mappings under both in vivo and ex vivo conditions.
Clinically, SLNs were identiﬁed in all patients (n = 24)
using the ex vivo strategy within 5 min after injection of
ﬂuorescent tracer. Also, 9 patients showed lymph node
involvement (N1 disease). In 1 patient, a 3-mm mesenteric
metastasis was found adjacent to a tumor-negative SLN.
Conclusions. The current pilot study shows proof of prin-
ciple that ex vivo NIR ﬂuorescence-guided SLN mapping
can provide high-sensitivity, rapid, and accurate identiﬁca-
tion of SLNs in colon and rectum. This creates an
experimentalplatformtotestoptimized,non-FDA-approved
NIR ﬂuorescent lymphatic tracers in a clinical setting.
The prognosis and quality of life for patients suffering
from colorectal cancer (CRC) depends on the extent and
quality of surgical treatment. Apart from tumor character-
istics (i.e., stage, differentiation grade), complete surgical
removal with en bloc regional lymphadenectomy is pivotal
for patient prognosis. Metastatic spread to regional lymph
nodes is one of the most important prognostic factors and
determines the need for adjuvant chemotherapy. The sen-
tinel lymph node (SLN) is the ﬁrst lymph node that
receives lymphatic drainage from a tumor, and identiﬁca-
tion of the SLN and analysis for tumor involvement should
predict the status of the remaining lymph nodes. The SLN
procedure is regarded standard of care in the treatment of
breast cancer and melanoma.
1–3 However, its added value
in colorectal cancer has not yet been established.
Retrospective studies on micrometastatic disease in
CRC and the risk of recurrence are conﬂicting.
4–6 Our
group has previously shown that ultrastaging of lymph
nodes with RT-PCR identiﬁes a subgroup of pN0 patients
with an inferior prognosis.
7,8 However, this methodology is
labor intensive and not used routinely. Identifying the SLN
 The Author(s) 2010. This article is published with open access
at Springerlink.com
First Received: 16 April 2010;
Published Online: 16 November 2010
A. L. Vahrmeijer, MD, PhD
e-mail: a.l.vahrmeijer@lumc.nl
Ann Surg Oncol (2011) 18:1006–1014
DOI 10.1245/s10434-010-1426-0in the surgical specimen provides the pathologist with an
opportunity to optimally stage the lymphatic basin beyond
standard H&E analysis of the regional nodes.
9 Published
results on identifying SLN in CRC show variable success
rates ranging from 58% to 100%.
10–20 Consequently, there
is ample room for improvement of mapping methodology.
In the majority of published studies of CRC patients,
subserosal, circumferential, and peritumoral injection of the
visible dye isosulfan blue has been used, both in vivo and ex
vivo.
12,13,15,19,21Isosulfanblueisdistributedrapidlythrough
the afferent lymphatic channels; however, because of their
small size, the dye particles can readily diffuse through the
true SLN to 2nd- and 3rd-tier nodes (a total of up to 21
‘‘sentinel’’ nodes are reported).
16 Isosulfan blue also stains
tissue an unnatural color and provides poor overall contrast.
Dyes that emit ﬂuorescence in the invisible, near-infrared
(NIR)portionoftheelectromagneticspectrum(700–900 nm)
have several advantages for SLN mapping. NIR light pene-
tratesrelativelydeepintolivingtissue,andtissueitselfhaslow
autoﬂuorescence in the NIR, resulting in a high signal-to-
backgroundratio.
22SinceNIRlightisnotvisibletothehuman
eye,thereisnochangetothelookofthesurgicalﬁeld.Several
clinicalstudieshavebeenpublishedonSLNmappinginbreast
cancer, gastric cancer, and colon cancer, using the clinically
available NIR probe indocyanine green.
23–27 However, these
studieswereperformedusingimagingsystemsthatdisplaythe
NIR signalwithout the visible image as a surgicalanatomical
reference.Ourgrouphasdevelopedasystem(FLARE)thatis
capable of displaying NIR signal and visible image (captured
byacolorvideocamera)simultaneouslyandcansuperimpose
the NIR signal over the color image.
28,29
Previously, our group reported the use of NIR light for
real-timeintraoperativeSLNmappingofthegastrointestinal
tract.
30,31 These and earlierstudies show clear advantagesof
NIR imaging over the conventional blue dyes.
32 Of pub-
lished organic molecules, the NIR ﬂuorophore HSA800
emerged as the molecule with the best overall performance
with respect to entry to the lymphatics, ﬂow to the SLN,
retentionintheSLN,ﬂuorescenceyield,andreproducibility.
Since HSA800 cannot be translated to the clinic without a
long and costly regulatory process, we hypothesized that ex
vivo SLN mapping in colon and rectal cancer could provide
all of the beneﬁts of NIR ﬂuorescence imaging over visible
blue dyes, without the need for regulatory approval, and
without risk to the patient.
MATERIALS AND METHODS
Lymphatic Tracers
The preparation of HSA800 (IRDye 800CW conjugated
to human serum albumin) has been described in detail
previously.
30 The ratio of ﬂuorophore (IRDye 800CW;
Li-Cor, Lincoln, NE) to albumin (HSA) was 3:1, estimated
using the extinction coefﬁcients of HSA (e280nm = 32,900
M
-1 cm
-1) and CW800 (e778nm = 240,000 M
-1 cm
-1)i n
phosphate-buffered saline (PBS). Peak absorbance and
emission of HSA800 were 778 and 795 nm, respectively. A
stock solution of 10 lM (in pig) or 50 lM (in human)
HSA800 in PBS, pH 7.4 was used for all injections.
Real-Time NIR Fluorescence Imaging
Preclinical SLN mapping was performed using the
FLARE image-guided surgery system as described in detail
previously.
29 The system is shown schematically in Fig. 1.
It consists of 2 wavelength isolated light sources: a
‘‘white’’ light source, generating 40,000 lx of 400–650 nm
light and a ‘‘near-infrared’’ light source, generating 12.5-
mW/cm
2 760-nm light over a 15-cm ﬁeld of view. Color
video and NIR ﬂuorescence images are simultaneously
acquired and displayed in real time using custom optics and
software that separate the color video and NIR ﬂuorescence
images.
29 A pseudocolored (lime green) merged image of
the color video and NIR ﬂuorescence images is also dis-
played. Clinical SLN mapping was performed using a
miniaturized version of FLARE (Mini-FLARE), which is
described in detail elsewhere (Troyan et al., manuscript in
preparation), with settings of 20,000 lx of 400–650 nm
‘‘white’’ light and 7 mW/cm
2 of 760-nm NIR light.
Animal Model Systems
Animals were housed in an AAALAC-certiﬁed facility
staffed by full-time veterinarians and were studied under
the supervision of an approved institutional protocol. This
protocol adhered to the ‘‘Guide for the Care and Use of
Laboratory Animals,’’ NRC 1996. Four female Yorkshire
pigs were purchased at 35 kg from E.M. Parsons and Sons
(Hadley, MA). All animals acclimated to the animal
facility for at least 48 h prior to experimentation. Anes-
thesia was induced with 4.4-mg/kg intramuscular Telazol
(Fort Dodge Labs, Fort Dodge, IA). The animal was then
intubated, and anesthesia was maintained with 2% isoﬂu-
rane (Baxter Healthcare Corporation, Deerﬁeld, IL).
Electrocardiogram (ECG), heart rate, oxygen saturation,
and body temperature were monitored throughout the
experiment. At the end of each experiment, euthanasia was
induced by rapid intravenous injection of 10 mL of
Fatal-Plus (Vortech Pharmaceuticals, Dearborn, MI), a
method consistent with the recommendation of the
Panel on Euthanasia of the American Veterinary Medical
Association.
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SLN mapping was performed using a 1-cc syringe
equipped with a 27-gauge, 0.5-in. needle. Each injection
consisted of 0.1 cc of HSA800 solution injected subsero-
sally, with the needle bevel facing upward. The injection
site was then gently massaged to stimulate lymphatic ﬂow
through increased hydrostatic pressure.
All animals received multiple injections at separate
locations in the colon and rectum. For each condition (in
vivo and ex vivo), 8 injections were performed in colon
and 8 injections were performed in the rectum, for a total of
32 injections. The NIR ﬂuorescence signal was monitored
using the FLARE system, and the SLN identiﬁed by
watching uninterrupted lymphatic ﬂow reach the ﬁrst
lymph node in real-time. After successful identiﬁcation, the
suspected lymph node was resected under ﬂuorescence
guidance, ﬁxed in 2% paraformaldehyde for 12 h, frozen in
LN2 using Tissue-Tek OCT, cryosectioned at 10 lm, and
analyzed by hematoxylin and eosin (H&E) staining.
After the in vivo injections, a subtotal colectomy and a
total mesorectal excision (TME) were performed. The
resected bowel specimens were placed on a table and at
locations that were not injected in vivo, 0.1 cc of HSA800
was injected subserosally, identical to the technique used
for in vivo injections. Tissue samples were also collected
and processed for histology as described previously.
Time needed to identify the SLN was compared between
in vivo and ex vivo conditions using an unpaired t test.
Assumption of equal variances was conﬁrmed by Levene’s
test. Statistical analyses, performed using SPSS software
version 17.0 (SPSS Inc., Chicago, IL), were 2-tailed, and
P\.05 was considered signiﬁcant.
Translation to the Clinic
A total of 24 consecutive patients undergoing curative-
intended surgery for colorectal cancer were included. This
study was approved by the Leiden University Medical
Center Medical Ethics Committee and performed in
accordance with the ethical standards of the Helsinki
Declaration of 1975. All patients underwent a standard
oncological resection including lymphadenectomy. In
cases of colon cancer, a segmental colonic resection was
performed; in cases of rectal cancer, a resection following
the principles of the total mesorectal excision (TME) was
performed. Directly following resection, bowel segments
were delivered fresh to the department of pathology, where
the specimen was opened anti-mesenterically by the
pathologist. In rectal cancer, surgical quality audit protocol
prohibits altering the perirectal fat in any way. Conse-
quently, in rectal cancer, the specimen was opened no
further than the rectosigmoid junction. Then, 1 cc of
50-lM HSA800 was injected submucosally circumferen-
tially with a 5-mm margin around the tumor, and the
injection site was massaged for 5 min. After 5 min, the
specimen was inspected using Mini-FLARE. Any ﬂuores-
cent hotspots were either marked with a suture or directly
resected for separate ﬁxation in 2% buffered formalin. The
specimen was ﬁxed using 2% buffered formalin for 24 h
(colon) or 48 h (rectum). After ﬁxation, ﬂuorescent nodes
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FIG. 1 FLARE image-guided surgery
system. The dichroic mirror directs
light below and above 650 nm to a
color video camera and NIR
ﬂuorescence camera, respectively,
permitting simultaneous acquisition of
color video and NIR ﬂuorescence
images. The surgeon’s monitor
includes a pseudocolored (lime green)
merge of the 2 images
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with the Mini-FLARE, and the specimen was processed
following the standard clinical protocol. For rectal cancer,
the specimen was processed using the slicing technique as
described by Quirke et al.
33 All lymph nodes (sentinel and
nonsentinel) were parafﬁn embedded and 4-lm sections
were H&E stained and subsequently analyzed by micro-
scope for the presence of tumor cells.
RESULTS
Preclinical NIR Fluorescence-Guided SLN
Identiﬁcation and Resection
In both in vivo and ex vivo conditions, all injections led
to a successful identiﬁcation of a SLN (Table 1). Shortly
after massaging the injection site, lymphatic ﬂow was
visualized on the NIR ﬂuorescence image (Fig. 2). In all
cases, lymphatic ﬂow terminated, without interruption, in 1
or more lymph nodes.
In the colon, we found no difference (Table 1) in the
time needed to identify the SLN between in vivo (56.4
seconds on average) and ex vivo (58.8 seconds on average)
conditions (t =- 0.111, P = .913). In the rectum, how-
ever, ex vivo injection led to a signiﬁcantly faster
identiﬁcation time for the SLN (26.8 seconds on average)
compared with in vivo (54.1 seconds; t = 2.942,
P = .011). Mean time between resection of the bowel and
ex vivo injection was 25 min (range 10–57 min). All
resected specimens (n = 32) were analyzed by H&E his-
tology and conﬁrmed to be lymph node tissue (Fig. 2c).
Clinical Ex Vivo NIR Fluorescence-Guided SLN
Mapping in Colorectal Cancer Patients
Patient and tumor characteristics are listed in Table 2.
In a preliminary set of experiments on n = 6 clinical
specimens, it was found that the subserosal injection
technique that worked so well with normal pig specimens
did not provide reliable results with human tumor speci-
mens (data not shown). Injecting subserosally and
circumferentially around human tumors resulted in a larger
injection site, which outshined lymph nodes close to the
tumor. To overcome this problem, a submucosal injection
technique was used.
16,34 It was also found that because of
the thickness of human specimens versus normal pig
specimens, a high concentration (50 lM) of HSA800 was
optimal.
Using this optimized strategy, in all 24 consecutive
patients, the procedure led to a successful detection of
SLNs. An example of the NIR ﬂuorescence images of the
procedure in colon cancer is shown in Fig. 3a. In rectal
cancer, quality control dictates that the specimen is not
altered prior to inking, ﬁxation, and slicing. As shown in
Fig. 3b, in rectal cancer, nodes were harvested successfully
after mesorectal slicing. Based on preﬁxation and postﬁx-
ation images, the formalin ﬁxation process did not appear
to alter NIR ﬂuorescence of HSA800. On average, per
specimen, 3.0 SLNs (range 1–5 SLNs) were identiﬁed by
NIR ﬂuorescence (Table 2). On average, a total of 15.9
lymph nodes (range 8–31 lymph nodes) were harvested per
specimen. Histological analysis showed that 9 of 24
patients had lymph node metastases. In all but 1 of those
cases, at least 1 of the SLNs contained tumor cells. In 1
patient, however, a small tumor deposit (3 mm) was found
in the mesentery, whereas the SLN was tumor negative.
Although no clear lymphatic tissue could be identiﬁed
(Fig. 4), pathological guidelines (WHO Classiﬁcation, 6th
edition) require that this lesion be classiﬁed as a lymph
node metastasis.
DISCUSSION
The presence of lymph node metastases in CRC patients
is the most important prognostic factor and an indication
for adjuvant chemotherapy. The presence of nodal
involvement decreases 5-year survival rates by 25–35%.
Long-term follow-up of adjuvant chemotherapy for
patients with stage III colon cancer showed a survival
beneﬁt with a 22–33% relative reduction in mortality.
35,36
Therefore, adequate staging in order to select patients who
may beneﬁt from adjuvant chemotherapy treatment is a
necessity. Moreover, patients without nodal disease (stage
I/II) still develop recurrent tumors in up to 25% of the cases
TABLE 1 Preclinical in vivo
and ex vivo identiﬁcation rates
for SLN mapping of pig colon
and rectum with HSA800
Organ Number of
injections (n)
Successful
identiﬁcations, n (%)
Number of SLNs
identiﬁed, n
Average identiﬁcation
time, sec
Colon
In vivo 8 8 (100%) 9 56.4 ± 48.3
Ex vivo 8 8 (100%) 8 58.8 ± 36.2
Rectum
In vivo 8 8 (100%) 10 54.1 ± 16.3
Ex vivo 8 8 (100%) 9 26.8 ± 21.3
Ex Vivo SLN Mapping Using Invisible NIR Light 1009within 5 years after surgical resection of the primary
tumor. This could be due to pathological understaging of
the tissue specimen at the time of primary treatment. SLN
mapping would be a useful method to circumvent this
problem.
12
Contradicting studies have also been published, showing
a high false negative rate of SLN mapping in colon can-
cer.
37,38 These so-called skip metastases, a tumor-negative
SLN combined with a positive non-SLN, are an important
limiting factor to the validity of the SLN procedure. In
colorectal cancer, skip metastases rates of 3–60% are
reported.
12,19 It has been suggested that these variable rates
are caused by the applied SLN identiﬁcation technique,
which could be overcome by a more reliable method of
identifying the SLN.
The current study shows proof of principle that by using
invisible NIR ﬂuorescent light and an optimal contrast
agent, identiﬁcation of the lymphatic channels and the SLN
is rapid and accurate. In the presented preclinical experi-
ments in pigs, both ex vivo NIR ﬂuorescence imaging of
the SLN as well as in vivo imaging showed similar results.
These preclinical results were successfully translated into a
pilot clinical study in which the SLN was identiﬁed ex vivo
in all patients. Whereas the NIR ﬂuorescent signal of
subserosal injections outshined lymph nodes located close
to the tumor, submucosal injections showed superior
results in patient specimens.
In 1 patient with three tumor-negative SLNs, a small
tumor metastasis was found in the mesenteric fat, without
any remnants of pre-existent lymphatic tissue (Fig. 4).
FIG. 2 In vivo and ex vivo
SLN mapping in colon and
rectum. a Identiﬁcation of the
SLN (arrows) in pig colon after
in vivo (top row) or ex vivo
(bottom row) injection
(arrowheads) of 0.1 cc of
10 lM HSA800. Shown are the
color video (left), NIR
ﬂuorescence (middle), and
pseudocolored (lime green)
merge of the 2 (right). b Ex vivo
identiﬁcation of the SLN
(arrow) after injection
(arrowhead) of 0.1 cc of 10 lM
HSA800 (top row). Resected
negative (-) and positive (?)
nodes in rectum (bottom row).
Shown are the color video (left),
NIR ﬂuorescence (middle), and
pseudocolored (lime green)
merge of the 2 (right). Note
accumulation of the dye at the
sinus entry site. c H&E
histological staining of the (?)
tissue section (1009
magniﬁcation) from b
1010 M. Hutteman et al.According to the WHO Classiﬁcation, 6th edition, such
tumor deposits are regarded as lymph node involvement.
This is supported by the conﬁguration of the lesion, being
encapsulated and round. Since the lesion was completely
effaced by tumor cells and lymphatic tissue was not
observable, it is plausible that no lymphatic drainage could
reach this node and in fact the NIR lymphatic tracer had
bypassed this mass. This phenomenon of lymph node
effacement is well known for breast cancer patients. The
fact that no ﬂuorescence could be measured in the parafﬁn
block of the lesion supports this hypothesis.
The great advantage of NIR ﬂuorescence imaging is that
the lymphatic channels traveling to the SLN are clearly
visualized in real time, even deep within the bowel mes-
entery. NIR ﬂuorescence imaging also permits the use of
small volumes (1 cc) of a colorless dye, and does not alter
the appearance of the surgical ﬁeld. Furthermore, the tim-
ing constraints of the technique we describe are very
ﬂexible, with successful identiﬁcation of the SLN up to 1 h
after resection of the bowel.
These results and earlier ﬁndings suggest that NIR
imaging has the potential to simplify the SLN procedure in
colorectal cancer, when compared with the use of visible
contrast agents such as isosulfan blue.
30,31 Therefore, lar-
ger studies comparing both techniques should be
performed. The ex vivo approach has certain advantages,
such as the use of contrast agents that are not yet approved
for in vivo administration.
11 The agent used in our study,
HSA800, has previously been compared with clinically
available agents such as indocyanine green and methylene
blue and has clear advantages over them.
30 Because of
conjugation of ﬂuorophore IRDye 800CW to human serum
albumin (HSA800), the hydrodynamic diameter of the
probe increases from less than 1 to 7.4 nm, thereby facil-
itating a better retention in the ﬁrst (sentinel) node
compared with blue dyes.
TABLE 2 Patient characteristics and results of sentinel lymph node mapping
Patient Age
(year)
Body
mass
index
Tumor
location
Tumor
differentiation
Tumor
size
(cm)
Tumor
stage
NIR-
identiﬁed
SLNs
Tumor
positive
SLNs
Total
LN
Total
LN?
False
negative
1 80 24 Cecum Moderately 6.0 T3 2 0 16 0 No
2 69 29 Cecum Moderately 5.5 T3 3 0 20 0 No
3 66 21 Cecum Moderately 6.7 T3 3 0 18 0 No
4 38 39 Cecum Moderately 3.5 T4 2 0 20 0 No
5 92 27 Cecum Moderately 4 T3 4 2 12 3 No
6 65 16 Cecum Moderately 1.3 T2 5 0 12 0 No
7 68 21 Ascending colon Moderately 5 T4 5 1 24 5 No
8 67 35 Ascending colon Moderately 4 T3 3 0 31 0 No
9 75 26 Ascending colon Moderately 4 T3 3 0 11 0 No
10 67 37 Ascending colon Moderately 2.3 T2 2 0 11 0 No
11 67 26 Ascending colon Moderately 5 T2 3 0 11 1 Yes
12 77 24 Hepatic ﬂexure Poorly 4.7 T3 2 1 16 1 No
13 91 29 Hepatic ﬂexure Moderately 3.8 T4 4 2 18 9 No
14 43 38 Hepatic ﬂexure Moderately 4 T3 3 0 11 0 No
15 75 26 Hepatic ﬂexure Moderately 4.5 T3 2 0 19 0 No
16 68 28 Transverse colon Moderately 2.5 T1 3 2 16 6 No
17 48 28 Sigmoid Well 3 T2 5 1 10 2 No
18 33 21 Sigmoid Moderately 4 T3 3 0 18 0 No
19 46 28 Sigmoid Moderately 4.5 T3 3 0 14 0 No
20 71 27 Rectum Poorly 2.6 T1 2 0 8 0 No
21 25 22 Rectum Moderately 5.5 T3 2 2 24 5 No
22 76 21 Rectum Minimal residual foci
a n/a
a T2 1 0 14 0 No
23 52 24 Rectum Moderately 3 T2 5 0 17 0 No
24 46 29 Rectum Moderately 2 T3 2 1 10 1 No
Mean 62.7 26.9 4.0 3.0 15.9
SLN sentinel lymph node, NIR near-infrared, LN lymph node, LN? lymph node with histologically proven metastases
Tumor stage was determined by TNM classiﬁcation
a Patient received neoadjuvant radiation and chemotherapy with a near-complete pathological response
Ex Vivo SLN Mapping Using Invisible NIR Light 1011Because the agent is not injected into the patient,
adverse reactions and patient safety are non-issues. Also,
because the injection is performed after resection, it is not
necessary that the surgeon performs the injection. There-
fore, this technique does not add any time to the surgery,
which is beneﬁcial for the patient and could improve
acceptance of the technique. In our hospital, the ﬂuorescent
dye is injected immediately after surgery at the department
of pathology, thereby eliminating any interference with the
surgical procedure. Using this technology, it should now be
possible to design even more effective lymphatic tracers
having higher ﬂuorescence intensity and better lymph node
retention.
The current NIR ﬂuorescence imaging technique does
not interfere with routine gross pathology and makes it
possible to detect the SLN in sliced sections of rectal
cancer specimens. Although neoadjuvant radiotherapy is
known to affect lymphatic channels, even in rectal cancer
patients that were treated with radiotherapy, SLNs were
identiﬁed. A possible explanation is that only small
amounts of HSA800 need to accumulate in the lymph node
to be detected by the Mini-FLARE imaging system. As the
mesorectum was not altered in any way, no lymphatic
channels were disrupted. Furthermore, because lymph ﬂow
is induced by massaging the ex vivo specimen, decreased
lymphatic ﬂow can be overcome.
Compared with published clinical studies on SLN
imaging using blue dyes, an important difference with the
current study is the condition of the injection site. The
current preclinical study was performed in healthy pigs,
whereas the clinical application of this technique was
performed in cancer patients. Large tumors are especially
known to alter and disrupt lymphatic channels. Since ear-
lier studies show that there is still sufﬁcient lymphatic ﬂow
to identify lymph nodes, we did not expect this to be a
major problem.
13,39 Viehl and colleagues showed that with
larger tumors, a larger amount of blue dye (0.5 cc per cm
tumor diameter) should be used to identify the SLN.
39 This
observation suggests an advantage for NIR ﬂuorescence
imaging, since in our pilot clinical study in which the mean
diameter of the tumors was 4.5 cm, a smaller amount of
dye (1 cc) was sufﬁcient to identify a ﬂuorescent signal in
the SLN.
In conclusion, our study suggests that ex vivo SLN
mapping using an optimal lymphatic tracer and invisible
FIG. 3 NIR ﬂuorescence-guided SLN mapping in patients with
colorectal cancer. a Ex vivo identiﬁcation of a SLN (arrow) in the
mesentery of the right hemicolon of a patient with a cecal
adenocarcinoma after submucosal peritumoral injection (arrowhead)
of 1 cc of 50 lM HSA800. Shown are the color video (left), NIR
ﬂuorescence (middle), and pseudocolored (lime green) merge of the 2
(right). b Ex vivo identiﬁcation of a SLN (arrow) in the mesorectum
of a patient with a rectal adenocarcinoma after submucosal peritu-
moral injection (arrowhead) of 1 cc of 50 lM HSA800. After 48 h
ﬁxation in 2% buffered formalin, tissue specimen was sliced and
imaged. Shown are the color video (left), NIR ﬂuorescence (middle),
and pseudocolored (lime green) merge of the 2 (right)
FIG. 4 Palpable metastatic lesion identiﬁed in the mesenteric fat.
H&E histological staining of a mesenteric metastasis (259 magni-
ﬁcation) not identiﬁed as a SLN. No nodal tissue was observed
1012 M. Hutteman et al.NIR ﬂuorescent light permits real-time imaging of lymph
ﬂow and identiﬁcation of the SLN in colon and rectal
cancer specimens.
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